Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer’s disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden.
Metrics to compare | GABAT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGABATPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.9x | 0.0x | −0.5x | |
PEG Ratio | −0.04 | 0.00 | 0.00 | |
Price/Book | 37.7x | 0.0x | 2.6x | |
Price / LTM Sales | - | 0.0x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 43.4% | |
Fair Value Upside | Unlock | 0.0% | 7.1% | Unlock |